Novo Nordisk expands lawsuits against makers of unapproved semaglutide drugs
ReutersAug 5, 2025 6:08 PM
Aug 5 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Tuesday it has filed 14 new lawsuits in the United States to stop companies from selling unapproved versions of semaglutide, the main ingredient in its popular weight loss and diabetes drugs, Wegovy and Ozempic.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
AMD Q2 FY2025 Earnings Review: Impressive Growth Stumbles on Export Control Hurdles
TradingKey - Advanced Micro Devices, Inc. (NASDAQ: AMD) released its Q2 FY2025 earnings on August 5, 2025, after market close, delivering robust results driven by record sales in its Data Center and Client segments. Despite a 32% YoY revenue increase, surpassing expectations, the stock dipped aroundTradingKey
3 hours ago
Post-NFP Shocker: What It Means for Your Portfolio
TradingKey - The latest data from the U.S. Bureau of Labor Statistics delivered a wake-up call. Job gains from the prior two months were revised down by 258,000 — a surprisingly large downgrade.TradingKey
21 hours ago
Novo Nordisk FY2025 Second Quarter Earnings Preview
Novo Nordisk’s Q2 2025 earnings report is expected to be released before the U.S. market opens on August 6.TradingKey
Mon, Aug 4
Lockheed Martin (LMT): Robust Backlog & Geopolitical Tailwinds Bolster Long-Term Outlook Despite Short-Term Project Setbacks
TradingKey - The U.S. is increasing defense spending significantly over the years due to rising global tensions and the need to modernize its military capabilities. The defense sector has outperformed broader markets fueled by reliable government contracts and innovation.TradingKey
Mon, Aug 4
